AG˹ٷ

STOCK TITAN

[Form 4] Zimmer Biomet Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Leidos Holdings, Inc. (LDOS) � Form 4 insider transaction

Chief Financial Officer Christopher R. Cage reported one transaction dated 06/30/2025.

  • Acquisition: 64.1944 shares of common stock credited at $0.00 per share. The shares represent dividend-equivalent rights that were automatically reinvested in the company’s Key Executive Stock Deferral Plan.
  • Post-transaction ownership: 29,288.682 indirect shares held via the deferral plan and 46,953 direct shares.

No derivative securities were involved and no sales were disclosed. The filing does not indicate any open-market purchases or dispositions; the recorded activity is routine and non-cash. Given the immaterial share amount relative to the executive’s existing holdings, the filing is unlikely to have a meaningful impact on LDOS’s share count or market perception.

Leidos Holdings, Inc. (LDOS) � Transazione interna Form 4

Il Chief Financial Officer Christopher R. Cage ha riportato una transazione datata 30/06/2025.

  • Acquisizione: 64,1944 azioni ordinarie accreditate a $0,00 per azione. Le azioni rappresentano diritti equivalenti ai dividendi reinvestiti automaticamente nel Piano di Rinuncia Azionaria per Dirigenti Chiave della società.
  • Possesso post-transazione: 29.288,682 azioni indirette detenute tramite il piano di rinuncia e 46.953 azioni dirette.

Non sono stati coinvolti titoli derivati né sono state effettuate vendite. Il deposito non indica acquisti o cessioni sul mercato aperto; l’attività registrata è di natura ordinaria e non comporta esborso di denaro. Considerando la quantità di azioni irrilevante rispetto alle partecipazioni esistenti del dirigente, il deposito difficilmente influenzerà in modo significativo il numero di azioni LDOS o la percezione del mercato.

Leidos Holdings, Inc. (LDOS) � Transacción interna Formulario 4

El Director Financiero Christopher R. Cage reportó una transacción fechada el 30/06/2025.

  • ܾó: 64.1944 acciones ordinarias acreditadas a $0.00 por acción. Las acciones representan derechos equivalentes a dividendos que se reinvirtieron automáticamente en el Plan de Diferimiento de Acciones para Ejecutivos Clave de la compañía.
  • Propiedad posterior a la transacción: 29,288.682 acciones indirectas mantenidas a través del plan de diferimiento y 46,953 acciones directas.

No se involucraron valores derivados ni se divulgaron ventas. La presentación no indica compras ni disposiciones en el mercado abierto; la actividad registrada es rutinaria y sin movimiento de efectivo. Dado el monto insignificante de acciones en relación con las participaciones existentes del ejecutivo, es poco probable que esta presentación tenga un impacto significativo en el número de acciones de LDOS o en la percepción del mercado.

Leidos Holdings, Inc. (LDOS) � Form 4 내부� 거래 보고

최고재무책임�(Chief Financial Officer) Christopher R. Cage가 2025� 6� 30일자 거래 하나� 보고했습니다.

  • 취득: 주당 $0.00� 64.1944 보통주가 적립되었습니�. 해당 주식은 회사� 핵심 임원 주식 이연 계획(Key Executive Stock Deferral Plan)� 자동 재투자된 배당� 상당 권리� 나타냅니�.
  • 거래 � 소유 현황: 이연 계획� 통해 보유 중인 간접 주식 29,288.682주와 직접 보유 주식 46,953주입니다.

파생 증권은 포함되지 않았으며 판매 내역� 없습니다. 제출� 보고서에� 공개 시장에서� 매수� 매도 내역� 없으�, 기록� 활동은 일상적이� 현금� 수반되지 않는 거래입니�. 경영� 보유 주식 대� 미미� 주식 수량으로 인해 이번 보고가 LDOS 주식 수나 시장 인식� � 영향� 미칠 가능성은 낮습니다.

Leidos Holdings, Inc. (LDOS) � Transaction d’initié Formulaire 4

Le Directeur Financier Christopher R. Cage a déclaré une transaction datée du 30/06/2025.

  • Acquisition : 64,1944 actions ordinaires créditées à 0,00 $ par action. Ces actions représentent des droits équivalents aux dividendes qui ont été automatiquement réinvestis dans le Plan de Report d’Actions des Cadres Clés de l’entreprise.
  • Possession après transaction : 29 288,682 actions indirectes détenues via le plan de report et 46 953 actions directes.

Aucun titre dérivé n’a été impliqué et aucune vente n’a été divulguée. Le dépôt ne mentionne aucun achat ou cession sur le marché ouvert ; l’activité enregistrée est de routine et sans échange monétaire. Étant donné le nombre insignifiant d’actions par rapport aux avoirs existants du dirigeant, il est peu probable que ce dépôt ait un impact significatif sur le nombre d’actions LDOS ou sur la perception du marché.

Leidos Holdings, Inc. (LDOS) � Insider-Transaktion Form 4

Finanzvorstand Christopher R. Cage meldete eine Transaktion vom 30.06.2025.

  • Erwerb: 64,1944 Stammaktien zu einem Preis von 0,00 $ pro Aktie. Die Aktien stellen Dividendenäquivalente dar, die automatisch im Key Executive Stock Deferral Plan des Unternehmens reinvestiert wurden.
  • Besitz nach der Transaktion: 29.288,682 indirekte Aktien, gehalten über den Deferral-Plan, und 46.953 direkte Aktien.

Es wurden keine Derivate gehandelt und keine Verkäufe gemeldet. Die Einreichung weist keine Käufe oder Verkäufe am offenen Markt aus; die aufgezeichnete Aktivität ist routinemäßig und nicht zahlungswirksam. Aufgrund der unerheblichen Aktienmenge im Verhältnis zum bestehenden Bestand des Geschäftsführers ist es unwahrscheinlich, dass die Einreichung einen bedeutenden Einfluss auf die Anzahl der LDOS-Aktien oder die Marktwahrnehmung hat.

Positive
  • CFO increased indirect holdings, albeit by only 64 shares, which marginally aligns executive incentives with shareholders.
Negative
  • Transaction size is immaterial (�0.0001% of shares outstanding) and provides no actionable insight into management’s outlook.

Insights

TL;DR: Routine dividend-equivalent share accrual; negligible market impact.

The CFO’s acquisition of 64 shares at no cost is a standard bookkeeping entry tied to deferred compensation. After the credit, his indirect holdings total roughly 29.3k shares, while direct ownership remains 46.9k shares. There is no evidence of discretionary buying or selling, and the transaction neither signals bullish nor bearish sentiment. Investors can treat the filing as administratively neutral.

Leidos Holdings, Inc. (LDOS) � Transazione interna Form 4

Il Chief Financial Officer Christopher R. Cage ha riportato una transazione datata 30/06/2025.

  • Acquisizione: 64,1944 azioni ordinarie accreditate a $0,00 per azione. Le azioni rappresentano diritti equivalenti ai dividendi reinvestiti automaticamente nel Piano di Rinuncia Azionaria per Dirigenti Chiave della società.
  • Possesso post-transazione: 29.288,682 azioni indirette detenute tramite il piano di rinuncia e 46.953 azioni dirette.

Non sono stati coinvolti titoli derivati né sono state effettuate vendite. Il deposito non indica acquisti o cessioni sul mercato aperto; l’attività registrata è di natura ordinaria e non comporta esborso di denaro. Considerando la quantità di azioni irrilevante rispetto alle partecipazioni esistenti del dirigente, il deposito difficilmente influenzerà in modo significativo il numero di azioni LDOS o la percezione del mercato.

Leidos Holdings, Inc. (LDOS) � Transacción interna Formulario 4

El Director Financiero Christopher R. Cage reportó una transacción fechada el 30/06/2025.

  • ܾó: 64.1944 acciones ordinarias acreditadas a $0.00 por acción. Las acciones representan derechos equivalentes a dividendos que se reinvirtieron automáticamente en el Plan de Diferimiento de Acciones para Ejecutivos Clave de la compañía.
  • Propiedad posterior a la transacción: 29,288.682 acciones indirectas mantenidas a través del plan de diferimiento y 46,953 acciones directas.

No se involucraron valores derivados ni se divulgaron ventas. La presentación no indica compras ni disposiciones en el mercado abierto; la actividad registrada es rutinaria y sin movimiento de efectivo. Dado el monto insignificante de acciones en relación con las participaciones existentes del ejecutivo, es poco probable que esta presentación tenga un impacto significativo en el número de acciones de LDOS o en la percepción del mercado.

Leidos Holdings, Inc. (LDOS) � Form 4 내부� 거래 보고

최고재무책임�(Chief Financial Officer) Christopher R. Cage가 2025� 6� 30일자 거래 하나� 보고했습니다.

  • 취득: 주당 $0.00� 64.1944 보통주가 적립되었습니�. 해당 주식은 회사� 핵심 임원 주식 이연 계획(Key Executive Stock Deferral Plan)� 자동 재투자된 배당� 상당 권리� 나타냅니�.
  • 거래 � 소유 현황: 이연 계획� 통해 보유 중인 간접 주식 29,288.682주와 직접 보유 주식 46,953주입니다.

파생 증권은 포함되지 않았으며 판매 내역� 없습니다. 제출� 보고서에� 공개 시장에서� 매수� 매도 내역� 없으�, 기록� 활동은 일상적이� 현금� 수반되지 않는 거래입니�. 경영� 보유 주식 대� 미미� 주식 수량으로 인해 이번 보고가 LDOS 주식 수나 시장 인식� � 영향� 미칠 가능성은 낮습니다.

Leidos Holdings, Inc. (LDOS) � Transaction d’initié Formulaire 4

Le Directeur Financier Christopher R. Cage a déclaré une transaction datée du 30/06/2025.

  • Acquisition : 64,1944 actions ordinaires créditées à 0,00 $ par action. Ces actions représentent des droits équivalents aux dividendes qui ont été automatiquement réinvestis dans le Plan de Report d’Actions des Cadres Clés de l’entreprise.
  • Possession après transaction : 29 288,682 actions indirectes détenues via le plan de report et 46 953 actions directes.

Aucun titre dérivé n’a été impliqué et aucune vente n’a été divulguée. Le dépôt ne mentionne aucun achat ou cession sur le marché ouvert ; l’activité enregistrée est de routine et sans échange monétaire. Étant donné le nombre insignifiant d’actions par rapport aux avoirs existants du dirigeant, il est peu probable que ce dépôt ait un impact significatif sur le nombre d’actions LDOS ou sur la perception du marché.

Leidos Holdings, Inc. (LDOS) � Insider-Transaktion Form 4

Finanzvorstand Christopher R. Cage meldete eine Transaktion vom 30.06.2025.

  • Erwerb: 64,1944 Stammaktien zu einem Preis von 0,00 $ pro Aktie. Die Aktien stellen Dividendenäquivalente dar, die automatisch im Key Executive Stock Deferral Plan des Unternehmens reinvestiert wurden.
  • Besitz nach der Transaktion: 29.288,682 indirekte Aktien, gehalten über den Deferral-Plan, und 46.953 direkte Aktien.

Es wurden keine Derivate gehandelt und keine Verkäufe gemeldet. Die Einreichung weist keine Käufe oder Verkäufe am offenen Markt aus; die aufgezeichnete Aktivität ist routinemäßig und nicht zahlungswirksam. Aufgrund der unerheblichen Aktienmenge im Verhältnis zum bestehenden Bestand des Geschäftsführers ist es unwahrscheinlich, dass die Einreichung einen bedeutenden Einfluss auf die Anzahl der LDOS-Aktien oder die Marktwahrnehmung hat.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kolli Sreelakshmi

(Last) (First) (Middle)
345 E. MAIN STREET

(Street)
WARSAW IN 46580

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units(1) $91.11(2) 06/30/2025 A 171.496 (3) (3) Common Stock 171.496 $0 5,221.199 D
Explanation of Responses:
1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
2. The Conversion or Exercise Price of Derivative Security is 1-for-1.
3. The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director.
/s/ Matthew R. St. Louis, Attorney-in-Fact for Sreelakshmi Kolli (power of attorney previously filed) 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many LDOS shares did the CFO acquire on 06/30/2025?

64.1944 shares were credited through dividend-equivalent rights at $0.00 per share.

What is Christopher Cage’s total LDOS share ownership after the transaction?

He now holds 29,288.682 indirect shares and 46,953 direct shares.

Was there any sale of LDOS shares reported in this Form 4?

No sales were reported; the filing shows only a small share accrual.

Does the transaction indicate insider sentiment toward LDOS stock?

No. The entry is an automatic, non-cash accrual and is not a discretionary purchase or sale.

What type of plan holds the newly acquired shares?

The shares reside in the Key Executive Stock Deferral Plan, a company deferred-compensation vehicle.
Zimmer Biomet

NYSE:ZBH

ZBH Rankings

ZBH Latest News

ZBH Latest SEC Filings

ZBH Stock Data

18.46B
197.53M
0.2%
93.68%
3.54%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
United States
WARSAW